Fostering a multidisciplinary approach to HIV vaccine development

With 37 million people living with HIV worldwide, and over 2 million new infections diagnosed each year, an effective vaccine is regarded as the most potent public health strategy for addressing the pandemic.  Despite the many advances in the understanding, treatment and prevention of HIV made over the past 30 years, the development of broadly-effective HIV vaccine has remained unachievable.

The European HIV Alliance (EHVA) is a five year project funded by the European Union’s Horizon 2020 Research and Innovation Programme designed to foster the development of an effective vaccine. The EHVA encompasses 39 partners, each with the expertise to promote a comprehensive approach to the development of an effective HIV vaccine. The international alliance, which includes academic and industrial research partners from all over Europe, as well as sub-Saharan Africa and North America, will work to discover and progress novel vaccine candidates through the clinic.

EHVA Press Release    > Project FactSheet (PDF)      > Newsletter 20 July 2016 (PDF)

News

  • World AIDS Day - December 1st

    World AIDS Day is held on the 1st December each year and is an opportunity for people worldwide to unite in the fight against HIV, show their support for people living with HIV and to commemorate people who have died. World AIDS Day was the first ever global health day, held for the first time in 1988

    More information here

  • IAS 2017 Conference on HIV Pathogenesis, Treatment and Prevention

    The IAS Conference on HIV Science is returning to Paris in 2017
    As in previous editions, IAS 2017 will bring together a large number of specialists for the purpose of discussing and learning about HIV treatment and prevention. Conferences and roundtables are scheduled, which will put attendees in contact with eminent specialists.

    More information coming soon

Partnering organizations

Drawing from 39 partner organizations, EHVA encompasses expertise in the fields of molecular biology, structural biology, vectorology, adjuvants delivery, immunology, clinical science and biostatics. The alliance is devised to approach the challenges that have hindered the development of a broadly effective vaccine, to date, from all possible angles.

The multidisciplinary-partnership alliance was initiated by Professor Yves Levy of the French Institute of Health (INSERM) and Professor Giuseppe Pantaleo of the Swiss Vaccine Research Institute...

READ MORE

EHVA goals

EHVA fosters a multidisciplinary approach to the challenge of developing broadly effective HIV vaccines.

EHVA’s programme primary goals are to:

  • To develop a Multidisciplinary Vaccine Platform (MVP) for prophylactic and therapeutic HIV vaccines
  • To move at least two novel prophylactic vaccine candidates to clinical development
  • To identify immune correlates associated with control of HIV replication following immunological intervention
  • To establish astrong scientific basis for further development of EHVA vaccine candidates in larger clinical trials
READ MORE
europa  

This project has received funding from the European Union's Horizon 2020 research
and innovation programme under grant agreement N° 681032